The use of magnesium sulphate and morphine vs. morphine-only in Irukandji syndrome: a retrospective review of ambulance data


box jellyfish

How to Cite

Rathbone J, Franklin R, Nimorakiotakis V. The use of magnesium sulphate and morphine vs. morphine-only in Irukandji syndrome: a retrospective review of ambulance data. Australasian Journal of Paramedicine [Internet]. 2019Nov.8 [cited 2022Aug.19];160. Available from:



In 2006, the Queensland Ambulance Service (QAS) approved the use of magnesium sulphate for the management of patients with Irukandji syndrome (IS). The aim of this study was to compare pain scores and hypertensive (systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg) patients who received intravenous morphine as their treatment (morphine group) over those who received a combination of intravenous morphine and magnesium (magnesium group).


A retrospective case review of all IS patients attended by the QAS between 2007 and 2014. A search of the QAS electronic data base found 112 patients had IS. Analyses in IBM SPSS v.22 was undertaken to determine the outcome in final pain scores and blood pressure between the two groups.


Pain reduction was statistically different (F=29.18; p<.01), between the morphine group and the magnesium group with mean numerical pain scores post-treatment of 4.91 (95% CI: 4.02–5.81) and 2.21 (95% CI: 1.66–2.76) respectively. There was a lower frequency of patients in the magnesium group who remained hypertensive on arrival at a medical facility, with a significant difference between mean arterial BP of 101 mmHg (95% CI: 96–105; p=.028) and diastolic BP of 84 mmHg (95% CI: 80–88; p=.029) post-treatment. Of the 54 cases in the magnesium group, 32 were normotensive post-treatment compared to only six from the morphine group (n=17).


There has been considerable difference of opinion as to the utility of magnesium in IS and a marked difference in the results of case series versus a small randomised control trial. This study suggests that the combination of morphine and magnesium is more effective in treating patients with IS than morphine alone.


Gershwin L, Richardson AJ, Winkel KD, et al. Biology and ecology of Irukandji jellyfish (Cnidaria: Cubozoa). Adv Mar Biol 2013;66:1-85.

Gershwin L-A. Two new species of box jellies (Cnidaria: Cubozoa: Carybdeida) from the central coast of Western Australia, both presumed to cause Irukandji syndrome. Records of the Western Australian Museum 2014;29:10-9.

Tibballs J, Li R, Tibballs HA, Gershwin LA, Winkel KD. Australian carybdeid jellyfish causing 'Irukandji syndrome'. Toxicon 2012;59:617-25.

Gershwin LA, de Nardi M, Winkel KD, Fenner PJ. Marine stingers: review of an under-recognized global coastal management issue. Coastal Management 2010;38:22-41.

Tibballs J, Hawdon G, Winkel K. Mechanism of cardiac failure in Irukandji syndrome and first aid treatment for stings. Anaesth Intensive Care 2001;29:552.

Corkeron MA. Magnesium infusion to treat Irukandji syndrome. Med J Aust 2003;178:411.

Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. Br J Anaesth 1999;83:302.

McCullagh N, Pereira P, Cullen P, et al. Randomised trial of magnesium in the treatment of Irukandji syndrome. Emerg Med Australas 2012;24:560-5.

Rathbone J, Franklin R, Gibbs C, Williams D. Role of magnesium sulphate in the management of Irukandji syndrome: a systematic review. ibid. 2017;29:9-17.

Fenner PJ. Dangerous Australian box jellyfish. SPUMS J 2005;35:76-83.

Carrette TJ, Underwood AH, Seymour JE. Irukandji syndrome: a widely misunderstood and poorly researched tropical marine envenoming. Diving Hyperb Med 2012;42:214-23.

Queensland Ambulance Service. Information Privacy Act 2009 (Qld). 2017. Available at: [Accessed 15 May 2017).

Service. QA. Clinical practice manual; drug therapy protocols. Available at: https://ambulanceqldgovau/clinicalhtml [Accessed 24 November 2016].

Parker L. Authorisation for the use of magnesium sulphate in Irukandji syndrome. In: Rathbone J, editor. Dates as to when magnesium was authorised for the use in Irukandji Syndrome. Editor QAS: Executive Manager-Clinical Policy Development; 2017.

Clawson JJ, Dernocoeur KB. Principles of emergency medical dispatch: Priority Press; 2003.

Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004;44:398-404.

Carr DB, Goudas LC. Acute pain. Lancet 1999;353:2051-8.

Begon S, Pickering G, Eschalier A, Dubray C. Magnesium increases morphine analgesic effect in different experimental models of pain. Anesthesiology 2002;96:627-32.

Pereira P. Irukandji Taskforce Guidelines for the emergency management of Irukandji syndrome. Available at: http://archiverubicon-foundationorg/xmlui/handle/123456789/9372 [Accessed 24 November 2016].

Pocock SJ. When to stop a clinical trial. BMJ 1992;305:235-40.

Pocock SJ. When (not) to stop a clinical trial for benefit. JAMA 2005;294:2228-30.

Rathbone J, Franklin R, Gibbs C, Williams D. Role of magnesium sulphate in the management of Irukandji syndrome: a systematic review. Emerg Med Australas 2017;29:9-17.

Gershwin L-a, Dabinett K. Comparison of eight types of protective clothing against Irukandji jellyfish stings. J Coas Res 2009;117-30.

Turner J. Building the evidence base in pre-hospital urgent and emergency care: a review of research evidence and priorities for future research. The University of Sheffield Medical Care Research Unit Sheffield, UK: Department of Health; 2010.